🔎 Trials Near Me

Home › Uveal Melanoma › Tennessee

Pag-aaral pangklinika para sa Uveal Melanoma sa Tennessee

6 pag-aaral para sa Uveal Melanoma ang naghahanap ng mga kalahok sa mga site sa Tennessee.

Mga Lungsod sa Tennessee

Opisyal na teksto ng pag-aaral (English)

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

  • Sarah Cannon Research Institute (SCRI), Nashville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07804186

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

  • Sarah Cannon Research Institute, Nashville
Nagre-recruitPhase 1/2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Hun 15, 2026 · NCT06940739

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

  • The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 8, 2026 · NCT03947385

Neoadjuvant Darovasertib in Primary Uveal Melanoma

  • SCRI Oncology Partners, Nashville
  • Vanderbilt Eye Institute, Nashville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT07015190

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  • The West Clinic, PLLC dba West Cancer Center, Germantown
  • University of Tennessee Medical Center, Knoxville
  • Sarah Cannon Research Institute, Nashville
  • at 1 pa
Nagre-recruitPhase 2/3
Lahat ng edad · Lahat ng kasarian · Na-update Abr 2, 2026 · NCT06581406

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

  • SCRI Oncology Partners, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 28, 2025 · NCT07136181

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.